Is ‘Hospital at home’ the new normal? UK healthtech Huma seals deal with Atos to fastrack integration


During the COVID-19 pandemic, immense pressure came on the world’s healthcare systems, exposing the weaknesses of current models that are overstretched with ageing populations.

Following the £91.88 million investment that it picked up last month, UK-based healthtech startup Huma is now in the headlines as it has sealed a five-year strategic global partnership with Atos. This partnership will help shift healthcare and clinical trials from hospital to home.

Besides this, the company is also gearing up to get a £17 million investment from digital transformation consultancy Atos for &D and go-to-market resources, including dedicated consulting and sales personnel. This will help fast-track the integration of the Huma platform with other leading clinical platforms, as well as develop a dedicated video module.

Huma is a medtech startup that aims to transform healthcare and research globally with its digital ‘hospital at home’ and decentralised clinical trial platform.

Partnership to power ‘hospitals at home’

The partnership between Huma and Atos will support pharmaceutical and research industries to run complex global decentralised clinical trials. Already, the platform is used in the US and across Europe for illnesses ranging from atrial fibrillation to diabetes to COVID-19.

With the combined approach, patients are monitored outside of hospital and given timely, proactive clinical intervention ahead of need, optimising the use of resources, improving patient outcomes and reducing long-term healthcare costs. The companies expect that the combined service will reach €100 million (nearly £72 million) revenue per year within the first four years.

Huma’s healthtech service is already deployed across Germany, England and the UAE and is estimated to have the potential to almost double hospital capacity.

Robert Vassoyan, Head of Health & Life Sciences business, Atos, said: “We have great excitement about this partnership, as we are convinced that Atos and Huma can drive a systemic shift from reactive to proactive models of care. Huma is the company we’ve been looking for in this important mission that resonates with each of us personally as we seek to improve the lives of our family, friends, neighbors and society. This is a partnership worthy of the mission.”

Dan Vahdat, CEO and founder of Huma, said: “This partnership takes us to a new league – we have already shown that we can create a service for a new disease area in a matter of weeks, as we did during the pandemic, and that we can go live with over 100 clinics in a day. Atos will supercharge our work so we can offer services at scale, anywhere in the world across delivery of care and pharma collaborations leading to more people living longer, fuller lives.”